Published:
ALS Therapeutics Reviewed by NeuroInvestment
NI Research has released the February issue of
NeuroInvestment. The issue features a review of ALS, and the search for
genuinely useful therapeutics for the treatment of this devastating
illness. Just as Alzheimer's lyses memory, and schizophrenia dissolves the
personality, ALS gradually destroys muscle control, leaving patients almost
invariably doomed to death from respiratory failure.
The contents of the February NeuroInvestment include:
1) The ALS programs covered in the review include those from Sangamo
Biosciences, Ceregene, CytRx, Ruxton Pharmaceuticals, Trophos,
Cambria Bioscience, Ono, Oxford Biomedica, NeuroNova, and Knopp
Neuroscience.
2) A review of Sangamo Biosciences, whose innovative platform also
addresses diabetic neuropathy and glioblastoma.
3) A pointed assessment of Medivation's Phase III plans for Dimebon
4) Commentary on Epix's Alzheimer's data embarrassment
5) Commentary on Lundbeck and Paion's stroke deal, Alzheimer's and
Enbrel, and some remarkable and recent assertions from the CEOs
of Shire Pharmaceuticals and Cephalon
About NeuroInvestment: NeuroInvestment is the independent, monthly review
of the neurotherapeutics area. A one-year corporate subscription is $1600,
email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery
outside North America. A three-month trial subscription is US$600.
NI Research is the leading publisher of independent research on the
neuropharmaceutical/therapeutic industry. NI Research has published
NeuroInvestment since 1995, and the Private CNS Company Review since 2003.
In 2007 lNI Research launched an annual compendium of all neuro-oriented
R&D programs organized by disorder, CNS Disorders/Therapeutics, as well as
an annual review of the Alzheimer's therapeutics area, Alzheimer's 2008.
NI Research also provides inlicensing consultation and custom research for
large and small pharmaceutical firms. NI Research has developed an
unmatched information base regarding both publicly and privately held
neuro-oriented companies.
Copyright © 2009, MarketWire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,Media and Entertainment:BooksandPublishing, PharmaceuticalsandBiotech:Biotech, ,CA,CARDIFF, CA
Search News
Daily News
